Microbiome Therapy for the Treatment of Neurological or Behavioral Disorders

Principal Investigator: 

David Artis, Michael Kors Professor in Immunology

Background & Unmet Need

  • The microbiota has been shown to influence our development, metabolism, and immunity
  • Alterations in the microbiota have been shown to modulate host behaviors, but the mechanisms by which this occurs remain poorly understood
  • Unmet Need: Identification of mechanisms involved in the “gut-brain axis” may improve our understanding of behavioral disorders and support therapeutic development

Technology Overview

  • The Technology: Microbiome-based therapies with the potential to prevent and treat numerous neurological and behavioral disorders
  • Discovery: Germ-free mice develop significantly altered neuronal activity and behaviors, particularly in fear extinction learning
  • Selective reintroduction of the microbiota restored behavioral deficits in adult mice
  • Several microbiome-derived metabolites were shown to be significantly down-regulated in germ-free mice
  • May be particularly relevant for individuals at risk of developing altered microbiota

Technology Applications

  • Prevention of ASD and other neuropsychiatric disorders in newborns with altered microbiota exposure (e.g., pre-term birth, C-section)
  • Treatment of ASD, schizophrenia, and related disorders in children and adults
  • Reintroduction of beneficial bacteria after antibiotic treatment or radiation therapy

Technology Advantages

  • Targets the gut-brain axis to ensure normal neurological development
  • May be administered as either probiotic compositions or small molecule metabolites

Figure of germ-free mice and those colonized with a single strain exhibit a significant extinction learning deficit compared to control mice.

Intellectual Property

Patents

  • US Application US20230026402A1: "Microbiota based therapies to promote mental health"

Cornell Reference

  • 9142

Contact Information

Brian Kelly, Ph.D.

For additional information please contact

Brian Kelly
Director, Business Development and Licensing
Phone: (646) 962-7041
Email: bjk44@cornell.edu